106 related articles for article (PubMed ID: 12750032)
1. Conformationally constrained butyrophenones as new pharmacological tools to study 5-HT 2A and 5-HT 2C receptor behaviours.
Brea J; Masaguer CF; Villazón M; Cadavid MI; Raviña E; Fontaine F; Dezi C; Pastor M; Sanz F; Loza MI
Eur J Med Chem; 2003 Apr; 38(4):433-40. PubMed ID: 12750032
[TBL] [Abstract][Full Text] [Related]
2. Conformationally constrained butyrophenones with affinity for dopamine (D(1), D(2), D(4)) and serotonin (5-HT(2A), 5-HT(2B), 5-HT(2C)) receptors: synthesis of aminomethylbenzo[b]furanones and their evaluation as antipsychotics.
Raviña E; Casariego I; Masaguer CF; Fontenla JA; Montenegro GY; Rivas ME; Loza MI; Enguix MJ; Villazon M; Cadavid MI; Demontis GC
J Med Chem; 2000 Nov; 43(24):4678-93. PubMed ID: 11101359
[TBL] [Abstract][Full Text] [Related]
3. New serotonin 5-HT(2A), 5-HT(2B), and 5-HT(2C) receptor antagonists: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo and heterocycloalkanones.
Brea J; Rodrigo J; Carrieri A; Sanz F; Cadavid MI; Enguix MJ; Villazón M; Mengod G; Caro Y; Masaguer CF; Raviña E; Centeno NB; Carotti A; Loza MI
J Med Chem; 2002 Jan; 45(1):54-71. PubMed ID: 11754579
[TBL] [Abstract][Full Text] [Related]
4. Conformationally constrained butyrophenones with mixed dopaminergic (D(2)) and serotoninergic (5-HT(2A), 5-HT(2C)) affinities: synthesis, pharmacology, 3D-QSAR, and molecular modeling of (aminoalkyl)benzo- and -thienocycloalkanones as putative atypical antipsychotics.
Raviña E; Negreira J; Cid J; Masaguer CF; Rosa E; Rivas ME; Fontenla JA; Loza MI; Tristán H; Cadavid MI; Sanz F; Lozoya E; Carotti A; Carrieri A
J Med Chem; 1999 Jul; 42(15):2774-97. PubMed ID: 10425088
[TBL] [Abstract][Full Text] [Related]
5. Different regulation of rat 5-HT(2A) and rat 5-HT(2C) receptors in NIH 3T3 cells upon exposure to 5-HT and pipamperone.
Oekelen DV; Jurzak M; Van de Wiel D; Van Hecke G; Luyten WH; Leysen JE
Eur J Pharmacol; 2001 Aug; 425(1):21-32. PubMed ID: 11672571
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological characterization of a series of geometrically constrained 5-HT(2A/2C) receptor ligands.
Chambers JJ; Parrish JC; Jensen NH; Kurrasch-Orbaugh DM; Marona-Lewicka D; Nichols DE
J Med Chem; 2003 Jul; 46(16):3526-35. PubMed ID: 12877591
[TBL] [Abstract][Full Text] [Related]
7. S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization.
Millan MJ; Mannoury la Cour C; Chanrion B; Dupuis DS; Di Cara B; Audinot V; Cussac D; Newman-Tancredi A; Kamal M; Boutin JA; Jockers R; Marin P; Bockaert J; Muller O; Dekeyne A; Lavielle G
J Pharmacol Exp Ther; 2012 Mar; 340(3):750-64. PubMed ID: 22178752
[TBL] [Abstract][Full Text] [Related]
8. RNA-editing of the 5-HT(2C) receptor alters agonist-receptor-effector coupling specificity.
Berg KA; Cropper JD; Niswender CM; Sanders-Bush E; Emeson RB; Clarke WP
Br J Pharmacol; 2001 Sep; 134(2):386-92. PubMed ID: 11564657
[TBL] [Abstract][Full Text] [Related]
9. Enantiospecific synthesis and pharmacological evaluation of a series of super-potent, conformationally restricted 5-HT(2A/2C) receptor agonists.
Chambers JJ; Kurrasch-Orbaugh DM; Parker MA; Nichols DE
J Med Chem; 2001 Mar; 44(6):1003-10. PubMed ID: 11300881
[TBL] [Abstract][Full Text] [Related]
10. Functional selectivity of hallucinogenic phenethylamine and phenylisopropylamine derivatives at human 5-hydroxytryptamine (5-HT)2A and 5-HT2C receptors.
Moya PR; Berg KA; Gutiérrez-Hernandez MA; Sáez-Briones P; Reyes-Parada M; Cassels BK; Clarke WP
J Pharmacol Exp Ther; 2007 Jun; 321(3):1054-61. PubMed ID: 17337633
[TBL] [Abstract][Full Text] [Related]
11. Modulation of 5-HT(2A) receptor-mediated head-twitch behaviour in the rat by 5-HT(2C) receptor agonists.
Vickers SP; Easton N; Malcolm CS; Allen NH; Porter RH; Bickerdike MJ; Kennett GA
Pharmacol Biochem Behav; 2001; 69(3-4):643-52. PubMed ID: 11509227
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
Knight AR; Misra A; Quirk K; Benwell K; Revell D; Kennett G; Bickerdike M
Naunyn Schmiedebergs Arch Pharmacol; 2004 Aug; 370(2):114-23. PubMed ID: 15322733
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade.
Wood MD; Scott C; Clarke K; Cato KJ; Patel N; Heath J; Worby A; Gordon L; Campbell L; Riley G; Davies CH; Gribble A; Jones DN
CNS Neurol Disord Drug Targets; 2006 Aug; 5(4):445-52. PubMed ID: 16918396
[TBL] [Abstract][Full Text] [Related]
14. Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist.
Dunlop J; Watts SW; Barrett JE; Coupet J; Harrison B; Mazandarani H; Nawoschik S; Pangalos MN; Ramamoorthy S; Schechter L; Smith D; Stack G; Zhang J; Zhang G; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2011 Jun; 337(3):673-80. PubMed ID: 21402690
[TBL] [Abstract][Full Text] [Related]
15. Position 5.46 of the serotonin 5-HT2A receptor contributes to a species-dependent variation for the 5-HT2C agonist (R)-9-ethyl-1,3,4,10b-tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one: impact on selectivity and toxicological evaluation.
Miller KJ; Wu GY; Varnes JG; Levesque P; Li J; Li D; Robl JA; Rossi KA; Wacker DA
Mol Pharmacol; 2009 Dec; 76(6):1211-9. PubMed ID: 19767451
[TBL] [Abstract][Full Text] [Related]
16. m-CPP hypolocomotion is selectively antagonized by compounds with high affinity for 5-HT(2C) receptors but not 5-HT(2A) or 5-HT(2B) receptors.
Gleason SD; Lucaites VL; Shannon HE; Nelson DL; Leander JD
Behav Pharmacol; 2001 Dec; 12(8):613-20. PubMed ID: 11856898
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of 5-hydroxytryptamine-induced contraction in the chicken gastrointestinal tract.
Kitazawa T; Ukai H; Komori S; Taneike T
Auton Autacoid Pharmacol; 2006 Apr; 26(2):157-68. PubMed ID: 16553644
[TBL] [Abstract][Full Text] [Related]
18. Differences in potency and efficacy of a series of phenylisopropylamine/phenylethylamine pairs at 5-HT(2A) and 5-HT(2C) receptors.
Acuña-Castillo C; Villalobos C; Moya PR; Sáez P; Cassels BK; Huidobro-Toro JP
Br J Pharmacol; 2002 Jun; 136(4):510-9. PubMed ID: 12055129
[TBL] [Abstract][Full Text] [Related]
19. 1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists.
Dowd CS; Herrick-Davis K; Egan C; DuPre A; Smith C; Teitler M; Glennon RA
J Med Chem; 2000 Aug; 43(16):3074-84. PubMed ID: 10956215
[TBL] [Abstract][Full Text] [Related]
20. Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines.
Blair JB; Kurrasch-Orbaugh D; Marona-Lewicka D; Cumbay MG; Watts VJ; Barker EL; Nichols DE
J Med Chem; 2000 Nov; 43(24):4701-10. PubMed ID: 11101361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
